- AU$167.96m
- AU$160.46m
- AU$27.77m
- 54
- 35
- 63
- 52
Annual balance sheet for Cyclopharm, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 12.7 | 1.87 | 29.2 | 20.3 | 11.7 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4.21 | 9.07 | 8.1 | 7.71 | 7.9 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 19.6 | 16 | 43.3 | 36.9 | 30.2 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 6.28 | 5.81 | 6.25 | 6.6 | 9.19 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 32.5 | 28.3 | 55.7 | 49.5 | 45.9 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.48 | 5.68 | 7.42 | 7.94 | 8.67 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 9.32 | 11.2 | 12.7 | 13 | 13.7 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 23.2 | 17.1 | 43.1 | 36.5 | 32.3 |
| Total Liabilities & Shareholders' Equity | 32.5 | 28.3 | 55.7 | 49.5 | 45.9 |
| Total Common Shares Outstanding |